• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

Follow-up: Prozac intrigue fizzles

Article

In February ( http://www.contemporarypediatrics.com/contpeds/article/articleDetail.jsp?id=147795), Updates reported an accusation made by the British Medical Journal (BMJ) that pharmaceutical manufacturer Eli Lilly & Co. had concealed documents linking the company's antidepressant Prozac (fluoxetine) to a heightened risk of suicide. Updates noted that Lilly denied the allegation but, regrettably, the February issue of Contemporary Pediatrics had already gone to press when BMJ editors retracted their statement and apologized to Lilly: "The BMJ accepts that Eli Lilly acted properly in relation to the disclosure of these documents ... and is happy to set the record straight and apologize."

Related Videos
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Ashley Gyura, DNP, CPNP-PC | Image Credit: Children's Minnesota
Congenital heart disease and associated genetic red flags
Traci Gonzales, MSN, APRN, CPNP-PC
© 2024 MJH Life Sciences

All rights reserved.